When was Kind Pharmaceuticals founded?

Kind Pharmaceuticals was founded in 2014.

Where is Kind Pharmaceuticals located?

Kind Pharmaceuticals is headquartered in Hangzhou, China.

Who is the current CEO of Kind Pharmaceuticals?

Liu Dong of Kind Pharmaceuticals. They have also founded 1 company.

Where does Kind Pharmaceuticals rank among its competitors?

Kind Pharmaceuticals ranks 2542nd amongst 3279 active competitors, of which 1119 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Kind Pharmaceuticals?

Kind Pharmaceuticals' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Among them, Immuneel secured the most recent funding round in June, 2026.

Kind Pharmaceuticals - 2026 Company Profile, Team & Competitors

Kind Pharmaceuticals is an unfunded company based in Hangzhou (China), founded in 2014 by Liu Dong. It operates as a Developer of treatments for anemia and other diseases. Kind Pharmaceuticals has not raised any funding yet. The company has 3279 active competitors, including 1119 funded and 774 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio.

Company Details

Developer of treatments for anemia and other diseases. It offers a lead candidate, AND017 a first-in-class hemoglobin elevating agent being developed for the treatment of chronic kidney disease, cancer-related anemia, and sickle cell disease. It also offer AND019 for breast cancer, and AND021 for kidney cancer.

Website: www.kindpharmaceutical.com
Email ID: *****@kindpharmaceutical.com
Phone Number: +86 **********

Key Metrics

Founded Year

2014

Location

Hangzhou, China

Stage

Unfunded

Ranked

2542^nd among 3279 active competitors

Similar Companies

Jazz Pharmaceuticals & 2984 more

View Kind Pharmaceuticals' full profile

Kind Pharmaceuticals has not raised any funding rounds yet.

The founders of Kind Pharmaceuticals is Liu Dong. Liu Dong is the CEO of Kind Pharmaceuticals.

Here are the details of Kind Pharmaceuticals' key team members:

Liu Dong: Founder & CEO of Kind Pharmaceuticals.

View details of Kind Pharmaceuticals's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Kind Pharmaceuticals include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of Kind Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
3rd	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, F-Prime Capital & 23 others	71/100
2542nd	Kind Pharmaceuticals 2014, Hangzhou (China), Unfunded	Developer of treatments for anemia and other diseases	-	-	24/100